LRMR vs. ORGO, ABUS, PRAX, PHAR, NUVB, SION, LENZ, DNTH, CRMD, and VECT
Should you be buying Larimar Therapeutics stock or one of its competitors? The main competitors of Larimar Therapeutics include Organogenesis (ORGO), Arbutus Biopharma (ABUS), Praxis Precision Medicines (PRAX), Pharming Group (PHAR), Nuvation Bio (NUVB), Sionna Therapeutics (SION), LENZ Therapeutics (LENZ), Dianthus Therapeutics (DNTH), CorMedix (CRMD), and VectivBio (VECT). These companies are all part of the "pharmaceutical products" industry.
Larimar Therapeutics vs.
Larimar Therapeutics (NASDAQ:LRMR) and Organogenesis (NASDAQ:ORGO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.
Larimar Therapeutics has a net margin of 0.00% compared to Organogenesis' net margin of -1.62%. Organogenesis' return on equity of -2.69% beat Larimar Therapeutics' return on equity.
91.9% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 49.6% of Organogenesis shares are owned by institutional investors. 3.5% of Larimar Therapeutics shares are owned by insiders. Comparatively, 36.9% of Organogenesis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, Organogenesis had 11 more articles in the media than Larimar Therapeutics. MarketBeat recorded 13 mentions for Organogenesis and 2 mentions for Larimar Therapeutics. Organogenesis' average media sentiment score of 0.51 beat Larimar Therapeutics' score of 0.00 indicating that Organogenesis is being referred to more favorably in the news media.
Organogenesis received 55 more outperform votes than Larimar Therapeutics when rated by MarketBeat users. However, 70.00% of users gave Larimar Therapeutics an outperform vote while only 65.99% of users gave Organogenesis an outperform vote.
Larimar Therapeutics presently has a consensus target price of $20.13, indicating a potential upside of 564.19%. Organogenesis has a consensus target price of $5.50, indicating a potential upside of 6.59%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Larimar Therapeutics is more favorable than Organogenesis.
Organogenesis has higher revenue and earnings than Larimar Therapeutics. Organogenesis is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.
Larimar Therapeutics has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500. Comparatively, Organogenesis has a beta of 1.66, indicating that its share price is 66% more volatile than the S&P 500.
Summary
Organogenesis beats Larimar Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Larimar Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LRMR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Larimar Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:LRMR) was last updated on 3/10/2025 by MarketBeat.com Staff
